FDA OT cybersecurity guidance reshapes pharmaceutical manufacturing security

At a glance

What this is: Elisity’s analysis says the FDA’s new OT guidance reframes pharmaceutical manufacturing security around connected production systems, complete asset visibility, zone-based segmentation, and security by design.

Why it matters: For IAM, PAM, NHI, and broader security teams, the key implication is that manufacturing access and segmentation must be governed as an operational control plane, not treated as a network afterthought.

Context

Pharmaceutical manufacturing OT is no longer an isolated control environment. As production lines, IIoT devices, robotics, and shared services become more connected, the security problem shifts from protecting a single endpoint to governing trust boundaries across plants, vendors, and production zones.

The FDA’s June 2025 white paper matters because it treats manufacturing security as patient safety and supply chain resilience, not just compliance. That places identity, segmentation, and asset inventory decisions inside the core control model, especially where equipment, shared services, and remote access intersect.

This is a typical pressure pattern for regulated manufacturing: operational complexity grows faster than legacy perimeter controls, and the security model has to catch up.

Key questions

Q: What is the first step when securing pharmaceutical OT environments under FDA guidance?

A: Start with a trustworthy OT asset inventory and zone model. You cannot enforce least privilege or prove compliance until you know which devices, embedded components, and communication paths exist in each production area. In regulated manufacturing, discovery comes before segmentation because the control boundary has to match operational reality.

Q: Why do flat OT networks increase risk in pharmaceutical manufacturing?

A: Flat networks create broad implicit trust, which makes lateral movement easier if a device, workstation, or remote path is compromised. In manufacturing, that can turn a local issue into a plant-wide operational incident. Zone and conduit design reduces that risk by constraining communication to the systems that actually need it.

Q: What are the signs that OT segmentation is failing in practice?

A: Look for maintenance paths that can reach more than one zone, credentials that remain usable after the job ends, and limited visibility into what the session actually touched. Those are signs that segmentation is still being enforced by assumption rather than by policy.

Q: How should security teams balance FDA compliance with plant uptime?

A: Treat compliance as a design problem rather than a retrofitting exercise. The best outcome is a zone-based model that preserves deterministic production traffic while removing unnecessary trust between systems. That allows security to strengthen containment without forcing broad operational disruption.

Technical breakdown

Why flat networks fail in pharmaceutical OT

A flat OT network assumes that everything inside the production environment can be trusted to communicate broadly, which breaks down once devices, vendors, and production systems become interdependent. In pharmaceutical manufacturing, that creates unnecessary lateral movement paths and makes containment difficult if one device or workstation is compromised. The FDA’s zone and conduit model instead groups assets by shared security requirements and limits communication to controlled channels. That matters because OT often prioritises uptime and deterministic function, so security controls must preserve process continuity while reducing the blast radius of compromise.

Practical implication: Treat segmentation as a manufacturing safety control, not just a network design preference.

Why asset visibility and SBOMs are foundational controls

OT environments often contain embedded modules, hidden components, and mixed-vendor equipment that operators do not fully see from the console. That makes complete inventory a prerequisite for any meaningful policy enforcement. Software bills of materials help explain what components exist, while device discovery reveals what is actually connected and communicating. Without those two layers, security teams cannot reliably classify systems, validate exposure, or prove that a zone boundary is complete. In regulated manufacturing, incomplete visibility is not merely a technical gap. It undermines compliance evidence and makes control scoping unreliable.

Practical implication: Build inventories that combine discovery, component transparency, and communication mapping before enforcing policy.

How identity-based microsegmentation maps to IEC 62443

IEC 62443’s zones and conduits model becomes far more practical when policies are attached to identities, device roles, and communication intent rather than static IP ranges. Identity-based microsegmentation lets policies follow assets as they move across lines or facilities, which is valuable in manufacturing environments where equipment is retooled or relocated. It also supports least privilege for operational communications, so a PLC only talks to approved HMI or quality systems. That reduces policy drift and makes enforcement more consistent across plants, especially when manual reconfiguration would otherwise be slow and error-prone.

Practical implication: Use identity-bound policies to preserve least privilege as equipment and processes change.

Threat narrative

Attacker objective: The attacker wants to interrupt manufacturing operations or degrade the integrity of medical product production at scale.

1. Entry often begins through exposed or overly connected OT systems, remote maintenance paths, or inadequately segmented devices inside a production environment.
2. Once inside, an attacker can move laterally across shared manufacturing infrastructure because flat networks and weak zone boundaries provide too much implicit trust.
3. The likely objective is disruption of production, manipulation of manufacturing processes, or broad operational downtime that affects product safety and supply continuity.

Breaches seen in the wild

• Schneider Electric Jira breach 2024: Credentials linked to a Lumma infostealer infection gave Hellcat access to Schneider Electric's Jira; 40GB and 400,000 user rows claimed.

Read and download The State of NHI & AI Agent Breach Report 2026, covering 200+ breaches impacting Non-Human Identities including AI Agents.

NHI Mgmt Group analysis

Zone and conduit architecture is now a governance requirement, not a design preference. The FDA’s guidance makes it clear that pharmaceutical manufacturing security must be organised around controlled communication boundaries rather than ambient trust. That is a structural shift for security governance because it turns segmentation into a compliance-relevant control plane. For practitioners, the lesson is that flat or weakly segmented OT networks no longer satisfy the risk profile of connected manufacturing.

Complete asset discovery is the prerequisite for any credible OT security programme. If embedded modules, hidden devices, and shared services are not inventoried, policy enforcement becomes partial and audit evidence becomes brittle. The article’s emphasis on SBOMs and classification shows that visibility is not an operational nicety. For practitioners, the control gap is not lack of tooling alone but lack of trustworthy scope.

Manufacturing trust boundary drift is the central failure mode this guidance addresses. The problem is not simply that OT is connected, but that each new device, vendor, or production dependency expands the set of systems that can influence patient safety. The FDA’s framing pushes security teams to govern those dependencies as continuously changing trust boundaries. For practitioners, that means the boundary itself must be designed, monitored, and revalidated over time.

Identity-based segmentation is the most practical bridge between compliance intent and plant reality. The article shows why static network controls struggle in environments where equipment moves, production lines differ, and access needs vary by task. Identity-linked policies reduce operational friction while preserving least privilege across zones. For practitioners, this is the point where OT governance becomes executable rather than theoretical.

What this signals

Manufacturing trust boundary drift: pharmaceutical security teams should expect the control problem to keep changing as connected devices, vendors, and production dependencies multiply. The practical response is to govern zones as living boundaries, not static diagrams, because every new integration can alter the attack surface and the compliance story.

The strongest programmes will tie OT inventory, segmentation, and audit evidence into one operating model rather than treating them as separate projects. That matters because regulated manufacturing environments need controls that are both defensible to auditors and executable on the plant floor.

Identity-based policy enforcement is becoming the most workable way to align security intent with production reality. Where equipment moves, lines differ, and access needs vary by task, controls have to follow the asset and its role rather than a fixed network location.

For practitioners

• Define manufacturing zones by process and risk Group OT assets by shared security requirements, production function, and patient-impact criticality before enforcing any conduit rules.
• Build a complete OT asset inventory Include embedded modules, software components, and communication paths so policy design is based on what is truly present, not what operators assume is present.
• Adopt identity-based least privilege for plant communications Attach rules to device identity and role so production systems can communicate only with approved peers, even when equipment moves across lines or facilities.
• Align security evidence to regulatory expectations Map inventory, segmentation, and logging outputs to the FDA guidance, IEC 62443 zone concepts, and any internal validation requirements used in audits.
• Test boundary controls before enforcement Validate that zone boundaries, conduits, and monitoring behave as intended in simulation or limited deployment before widening to full production.

Key takeaways

• The FDA’s OT guidance pushes pharmaceutical manufacturing security toward explicit trust boundaries, not broad internal trust.
• Complete visibility into connected assets, embedded components, and communication paths is now a prerequisite for enforceable OT policy.
• The most defensible control posture combines zone-based segmentation with identity-linked least privilege and continuous validation.

Key terms

• Zone And Conduit Architecture: A security model that groups assets with similar requirements into zones and allows communication only through controlled conduits. In OT environments, it limits lateral movement and turns segmentation into an explicit policy decision instead of a flat network assumption.
• Identity-based Microsegmentation: A segmentation approach that uses identity, context, and policy to decide whether a connection should be allowed inside a network zone. In OT, it helps reduce lateral movement without relying only on IP addresses or broad subnet rules.
• Software Bill of Materials: A software bill of materials is an inventory of the components and dependencies used in an application. It helps teams identify what they shipped, but it becomes most useful when paired with source verification, signature checks, and policy enforcement for third-party code.
• Operational Technology: Operational Technology is the hardware and software that monitors or controls physical processes such as manufacturing lines, utilities, and transportation systems. Unlike standard IT, OT prioritises uptime and safety, so identity controls must be precise enough to reduce risk without interrupting essential operations.

Deepen your knowledge

NHI Mgmt Group covers identity security, NHI governance, and agentic AI through independent research, practitioner guides, and the NHI Foundation Level course. It is built for security leaders who need to connect identity control with broader operational and compliance programmes.